Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FIORINAL vs ALLZITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.
Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Relief of tension-type headache,Relief of migraine headache (off-label)
Sedation,Short-term treatment of insomnia,Management of seizure disorders (generalized tonic-clonic and partial seizures),Preoperative anxiety
1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.
Butalbital 35-50 hours, aspirin 15-20 minutes (salicylate 2-3 hours at low doses, >20 hours at high doses), caffeine 3-5 hours. Prolonged in hepatic/renal impairment.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 8-12 hours in renal impairment.
Butalbital is extensively metabolized in the liver via hydroxylation and glucuronidation, primarily by CYP2C9 and CYP2C19. Aspirin is hydrolyzed to salicylic acid, then conjugated with glycine (salicyluric acid) and glucuronidated. Caffeine is metabolized by CYP1A2 to paraxanthine, theobromine, and theophylline.
Primarily hepatic via CYP2C9, CYP2C19, and glucuronidation; metabolized to inactive metabolites (e.g., p-hydroxyphenobarbital) that are excreted renally.
Renal: 60% butalbital (mostly unchanged), 10% aspirin (salicylates, majorly as metabolites), 3% caffeine (metabolites and unchanged). Fecal: <5% overall.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other.
Butalbital 20-40% (albumin), aspirin 80-90% (albumin, concentration-dependent), caffeine 25-36% (albumin).
92% bound to albumin and alpha-1-acid glycoprotein.
Butalbital 0.8 L/kg, aspirin 0.15-0.2 L/kg, caffeine 0.6-0.8 L/kg. Indicates extensive tissue distribution for butalbital and caffeine.
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution.
Oral: butalbital ~100%, aspirin 50-75% (first-pass metabolism), caffeine ~100%.
Oral: 85-90% due to first-pass metabolism; intravenous: 100%.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen accumulation. Use with caution in moderate impairment.
GFR 30-50 m L/min: 50% dose reduction; GFR <30 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For mild to moderate (Child-Pugh A or B), reduce dose by 50% or extend dosing interval.
Child-Pugh Class B: 50% dose reduction; Child-Pugh Class C: avoid use.
Not recommended for pediatric use; safety and efficacy not established.
0.1-0.2 mg/kg orally every 4-6 hours as needed; maximum single dose 5 mg; not to exceed 20 mg per day.
Start at lowest effective dose (e.g., 1 capsule every 4 hours) due to increased sensitivity to butalbital (sedation, confusion) and risk of acetaminophen hepatotoxicity; maximum daily acetaminophen dose 2 g.
Initiate at 2.5 mg orally every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
None.
Risk of respiratory depression, particularly with rapid IV administration or excessive doses; co-administration with CNS depressants (e.g., opioids, alcohol) may exacerbate this effect. Use in pregnancy may cause fetal harm (teratogenic effects).
Risk of Reye's syndrome in children with viral illness,Aspirin hypersensitivity (e.g., asthma, nasal polyps),Gastrointestinal bleeding and ulceration,Hepatic impairment due to butalbital metabolism,Caffeine overdose from excessive use,Dependence and withdrawal with prolonged butalbital use
Respiratory depression, CNS depression, dependence and withdrawal (taper gradually), paradoxical excitation (especially in elderly), use in hepatic or renal impairment, drug interactions with warfarin, oral contraceptives, and corticosteroids.
Hypersensitivity to butalbital, aspirin, or caffeine,Active peptic ulcer disease,Hemophilia or bleeding disorders,Concomitant use of anticoagulants,Children with chickenpox or influenza-like symptoms (risk of Reye's syndrome),Severe hepatic or renal impairment,Porphyria
Hypersensitivity to barbiturates, severe respiratory insufficiency, history of porphyria, severe hepatic impairment, pregnancy (especially first trimester).
Avoid excessive caffeine intake from coffee, tea, energy drinks, or chocolate as it may compound caffeine's stimulant effects and increase anxiety or insomnia. Alcohol should be strictly avoided due to additive CNS depression and increased GI bleeding risk with aspirin. No specific food restrictions besides moderation of caffeine-containing foods.
Avoid excessive alcohol consumption; may increase hepatotoxicity. No significant food interactions. Take with or without food; food may reduce GI upset.
First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause premature closure of ductus arteriosus. Third trimester: Aspirin increases risk of intracranial hemorrhage, premature closure of ductus arteriosus; butalbital may cause neonatal withdrawal. Caffeine is not a major teratogen but high doses may increase miscarriage risk.
Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbiturate use may lead to neonatal withdrawal and coagulation defects due to vitamin K deficiency; use only if benefit outweighs risk.
Aspirin excreted in milk (M/P ratio ~0.03-0.3); risk of Reye syndrome. Butalbital excreted in low amounts; may cause neonatal sedation. Caffeine excreted (M/P ~0.5-0.7); may cause irritability. Avoid breastfeeding during chronic use.
Butalbital and acetaminophen are excreted into breast milk in low amounts. Caffeine also enters milk. M/P ratio not established for butalbital. Use caution; monitor infant for sedation, poor feeding. American Academy of Pediatrics considers butalbital compatible with breastfeeding but avoid prolonged use.
Due to increased renal clearance and volume of distribution, butalbital may require dose increase; aspirin may need higher doses due to increased plasma volume; no specific adjustment for caffeine. Monitor clinical response and toxicity.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, hepatic metabolism) may reduce butalbital levels; clinical efficacy not well studied. Use lowest effective dose shortest duration. Acetaminophen doses remain standard (<4 g/day). Avoid caffeine >300 mg/day.
FIORINAL (butalbital/aspirin/caffeine) is a barbiturate-containing combination analgesic. Due to butalbital's high abuse potential and risk of withdrawal, it is reserved for tension-type headaches refractory to non-barbiturate therapies. Monitor for signs of barbiturate dependence, and limit quantity dispensed. Avoid in patients with porphyria, severe hepatic impairment, or hemorrhagic disorders (aspirin component). Caffeine may exacerbate anxiety or insomnia.
ALLZITAL is a combination analgesic containing acetaminophen and tramadol. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcohol intoxication. Maximum daily acetaminophen dose is 4000 mg; reduce in hepatic risk. Tramadol may lower seizure threshold; use cautiously in epilepsy. Not recommended in breastfeeding due to tramadol excretion. Adjust dose in renal impairment (Cr Cl <30 m L/min: extended interval). Discontinue gradually to avoid withdrawal.
This medication contains butalbital, which can be habit-forming; do not exceed prescribed dose or duration.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,Do not drive or operate heavy machinery until you know how this drug affects you.,Take with food to reduce stomach upset; if you experience black or bloody stools, stop and seek immediate medical attention (signs of GI bleeding from aspirin).,Do not use more than directed; sudden discontinuation can cause withdrawal symptoms (anxiety, tremors, seizures).,Keep out of reach of children; overdose may be fatal.
Do not exceed 8 tablets per day due to acetaminophen liver risk.,Avoid alcohol and other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until effect known.,Report signs of serotonin syndrome (agitation, hallucinations, rapid heart rate).,Do not stop suddenly; taper to prevent withdrawal symptoms.,Store at room temperature away from moisture.,Use only as prescribed; risk of dependence with tramadol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FIORINAL vs ALLZITAL, answered by our medical review team.
FIORINAL is a Barbiturate Analgesic Combination that works by FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.. ALLZITAL is a Barbiturate Analgesic Combination that works by Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FIORINAL and ALLZITAL depend on the specific clinical indication. These are both Barbiturate Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FIORINAL is: 1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. The standard adult dose of ALLZITAL is: 5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FIORINAL and ALLZITAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FIORINAL is classified as Category C. First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause prem. ALLZITAL is classified as Category C. Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbitu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.